THE MANAGEMENT OF anticoagulation for cardiopul-monary bypass (CPB) in patients with antiphospholipid antibodies is challenging because antiphospholipid antibodies increase the risk for arterial and venous thrombosis and affect commonly used in vitro coagulation assays such as the kaolin-activated coagulation time.Previous reports have described successful anticoagulation monitoring in these patients using anti-factor Xa measurements, the diatomaceous earth-activated coagulation time, and laboratory plasma heparin concentrations.In this report, the authors describe an alternative strategy using the HepCon HMS Plus point-of-care testing system (Medtronic, Englewood, CO). This strategy may be helpful when the other previously described modalities are not available.
展开▼
机译：患有抗磷脂抗体的患者进行心肺旁路抗凝治疗的挑战性很大，因为抗磷脂抗体会增加动脉和静脉血栓形成的风险并影响常用的体外凝血测定，例如高岭土活化的凝血时间。描述了使用抗Xa因子测量，硅藻土活化凝血时间和实验室血浆肝素浓度对这些患者进行成功的抗凝监测。在本报告中，作者描述了使用HepCon HMS Plus即时检验系统的替代策略（Medtronic，Englewood，CO）。当其他先前描述的模式不可用时，此策略可能会有所帮助。
展开▼
